In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

Activation of certain memory B cells may be driving systemic lupus erythematosus incidence in individuals who had ...

Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...

Background Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric systemic lupus ...

Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

New research identifies age, anti-β2GP1 antibodies, and low complement C3 as key risk factors for cerebral small vessel ...

Findings showed a higher percentage of participants on obinutuzumab achieved a minimum 4-point improvement in SRI-4 at 52 weeks vs standard therapy. Topline data were announced from a phase 3 trial ...

For the patient who presents with a new diagnosis of SLE, or for the one who has a flare in previously established disease, the immediate need is to achieve control of the inflammatory process. In ...